Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 312

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 312
---
,423 

The accompanying notes are an integral part of these consolidated financial statements. 

117

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share data and earnings per share amounts)

Year Ended December 31,20242023RevenueProduct sales, net$25,983 $24,354 Total revenue25,983 24,354 Operating expensesSelling, general and administrative36,749 44,549 Research and development 51,030 48,929 Restructuring charges2,638 — Cost of goods sold3,024 2,809 Total operating expenses93,441 96,287 Loss from operations(67,458)(71,933)Other income (expense)Foreign exchange loss(4)(1)Interest income3,925 6,400 Interest expense(154)(231)Total other income (expense), net3,767 6,168 Loss before income tax expense(63,691)(65,765)Income tax expense— — Net loss$(63,691)$(65,765)Other comprehensive loss:Unrealized (loss) income on available-for-sale debt securities(11)142 Comprehensive loss$(63,702)$(65,623)Net loss per share, basic and diluted$(2.36)$(2.44)Weighted average number of common shares outstanding, basic and diluted27,029,942 26,917,967 

The accompanying notes are an integral part of these consolidated financial statements. 

118

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Stockholders’ Equity

(in thousands, including share amounts) 

Stockholders’ EquityCommon StockAdditional Paid-In Capital Accumulated Other Comprehensive (Loss) IncomeAccumulated Deficit Total Stockholders' EquitySharesPar ValueBalance at December 31, 202224,435 $2 $361,689 $(115)$(203,198)$158,378 Issuance of common stock upon exercise of stock options42 — 78 — — 78 Share-based compensation expense— — 11,954 — — 11,954 Issuance of shares under the employee stock purchase plan77 — 408 — — 408 Unrealized gain on investments, net of tax— — — 142 —